argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Tim Van Hauwermeiren, the company's CEO, will deliver a presentation on Monday, January 13, 2025 at 9:45 a.m. PT.
The presentation will be accessible through a live webcast on the Investors section of the argenx website (argenx.com/investors). A replay option will remain available on the company's website for approximately 30 days after the presentation.
argenx (Euronext e Nasdaq: ARGX), un'azienda globale di immunologia focalizzata su gravi malattie autoimmuni, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Tim Van Hauwermeiren, CEO dell'azienda, presenterà un intervento lunedì 13 gennaio 2025 alle 9:45 a.m. PT.
La presentazione sarà accessibile tramite una diretta streaming nella sezione Investitori del sito web di argenx (argenx.com/investors). Sarà disponibile anche un'opzione di replay sul sito web dell'azienda per circa 30 giorni dopo la presentazione.
argenx (Euronext y Nasdaq: ARGX), una empresa global de inmunología centrada en enfermedades autoinmunes severas, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. Tim Van Hauwermeiren, el CEO de la empresa, dará una presentación el lunes 13 de enero de 2025 a las 9:45 a.m. PT.
La presentación estará disponible a través de una transmisión en vivo en la sección de Inversores del sitio web de argenx (argenx.com/investors). También habrá una opción de repetición que estará disponible en el sitio web de la empresa durante aproximadamente 30 días después de la presentación.
argenx (Euronext 및 Nasdaq: ARGX)는 심각한 자가면역 질환에 초점을 맞춘 글로벌 면역학 회사로, 43회 연례 J.P. Morgan Healthcare 콘퍼런스에 참가한다고 발표했습니다. 회사의 CEO인 Tim Van Hauwermeiren은 2025년 1월 13일 월요일 오전 9시 45분 PT에 발표를 진행할 예정입니다.
발표는 argenx 웹사이트(argenx.com/investors)의 투자자 섹션을 통해 실시간 웹캐스트로 시청할 수 있습니다. 이후 발표에 대한 재생 옵션은 약 30일 동안 회사 웹사이트에서 이용 가능합니다.
argenx (Euronext et Nasdaq : ARGX), une entreprise mondiale d'immunologie axée sur les maladies auto-immunes graves, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Tim Van Hauwermeiren, le PDG de l'entreprise, fera une présentation le lundi 13 janvier 2025 à 9h45 PT.
La présentation sera accessible par le biais d'une diffusion en direct sur la section Investisseurs du site web d'argenx (argenx.com/investors). Une option de rediffusion sera également disponible sur le site web de l'entreprise pendant environ 30 jours après la présentation.
argenx (Euronext & Nasdaq: ARGX), ein globales Immunologie-Unternehmen, das sich auf schwere Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Konferenz angekündigt. Tim Van Hauwermeiren, der CEO des Unternehmens, wird am Montag, den 13. Januar 2025 um 9:45 Uhr PT eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast im Investorenbereich der argenx-Website (argenx.com/investors) zugänglich sein. Eine Wiederholungsoption wird auf der Unternehmenswebsite für etwa 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
January 6, 2025
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
FAQ
When is argenx (ARGX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch argenx's (ARGX) J.P. Morgan Healthcare Conference presentation?
How long will the replay of argenx's (ARGX) J.P. Morgan presentation be available?
Who will represent argenx (ARGX) at the 2025 J.P. Morgan Healthcare Conference?
